Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Graefe's Archive for Clinical and Experimental Ophthalmology
Erschienen in:

25.05.2023 | Retinal Disorders

Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience

verfasst von: Kenneth J. Taubenslag, Edward F. Cherney, Shriji N. Patel, Janice C. Law, Anthony B. Daniels, Stephen J. Kim

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Increasing rates of antibiotic resistance in endophthalmitis have been reported. This study examines outcomes of triple therapy with intravitreal vancomycin, ceftazidime, and moxifloxacin for endophthalmitis.

Methods

Retrospective, consecutive series of all patients treated with abovementioned intravitreal antibiotics from January 2009 to June 2021. Percentages of eyes attaining greater than or equal to 20/200 and 20/50 Snellen visual acuities and adverse events were evaluated.

Results

112 eyes met inclusion criteria. 63 of 112 eyes (56%) achieved a visual acuity of 20/200 during follow-up, with 39 (35%) returning to at least 20/50. In subgroup analysis, 23 of 24 (96%) eyes with post-cataract endophthalmitis obtained ≥ 20/200 acuity and 21 of 24 (88%) obtained ≥ 20/50 acuity during follow-up. There were no cases of macular infarction.

Conclusions

Intravitreal moxifloxacin (160 µg/0.1 mL) was well tolerated as an adjunct to vancomycin and ceftazidime for bacterial endophthalmitis. Use of this novel combination offers several theoretical advantages compared to standard therapy with two antibiotics, including expanded gram-negative coverage and potential synergy, and may be particularly valuable in geographies where the local antibiogram supports empiric use. Further study is merited to verify the safety and efficacy profile.
Literatur
1.
Han DP, Wisniewski SR, Wilson LA et al (1996) Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 122:1–17CrossRefPubMed
2.
Gentile RC, Shukla S, Shah M et al (2014) Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology 121:1634–1642CrossRefPubMed
3.
Reddy AK, Reddy RR, Paruvelli MR et al (2015) Susceptibility of bacterial isolates to vancomycin and ceftazidime from patients with endophthalmitis: Is there a need to change the empirical therapy in suspected bacterial endophthalmitis? Int Ophthalmol 35:37–42CrossRefPubMed
4.
Jindal A, Pathengay A, Khera M et al (2013) Combined ceftazidime and amikacin resistance among Gram-negative isolates in acute-onset postoperative endophthalmitis: prevalence, antimicrobial susceptibilities, and visual acuity outcome. J Ophthalmic Inflamm Infect 3:62CrossRefPubMedPubMedCentral
5.
Pathengay A, Moreker MR, Puthussery R et al (2011) Clinical and microbiologic review of culture-proven endophthalmitis caused by multidrug-resistant bacteria in patients seen at a tertiary eye care center in southern India. Retina 31:1806–1811CrossRefPubMed
6.
Choi EY, Han JY, Lee H et al (2019) Impact of antibiotic resistance of pathogens and early vitrectomy on the prognosis of infectious endophthalmitis: a 10-year retrospective study. Graefes Arch Clin Exp Ophthalmol 257:805–813CrossRefPubMed
7.
Relhan N, Albini TA, Pathengay A et al (2016) Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment. Br J Ophthalmol 100:446–452CrossRefPubMed
8.
Shivaramaiah HS, Relhan N, Pathengay A et al (2018) Endophthalmitis caused by gram-positive bacteria resistant to vancomycin: Clinical settings, causative organisms, antimicrobial susceptibilities, and treatment outcomes. Am J Ophthalmol Case Rep 10:211–214CrossRefPubMedPubMedCentral
9.
Miyake H, Miyazaki D, Shimizu Y et al (2019) Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells. Sci Rep 9:9745CrossRefPubMedPubMedCentral
10.
Kernt M, Neubauer AS, Ulbig MW et al (2008) In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment. J Cataract Refract Surg 34:480–488CrossRefPubMed
11.
Aydin E, Kazi AA, Peyman GA, Esfahani MR (2006) Intravitreal toxicity of moxifloxacin. Retina 26:187–190CrossRefPubMed
12.
Gao H, Pennesi ME, Qiao X et al (2006) Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci 47:1606–1611CrossRefPubMed
13.
Sakalar YB, Ozekinci S, Celen MK (2011) Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone. J Ocul Pharmacol Ther 27:593–598CrossRefPubMed
14.
Ermis SS, Cetinkaya Z, Kiyici H et al (2007) Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis. Curr Eye Res 32:337–344CrossRefPubMed
15.
Jacobs DJ, Grube TJ, Flynn HW et al (2013) Intravitreal moxifloxacin in the management of Ochrobactrum intermedium endophthalmitis due to metallic intraocular foreign body. Clin Ophthalmol 7:1727–1730CrossRefPubMedPubMedCentral
16.
Agarwal A, Nagpal M (2021) Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety. Indian J Ophthalmol 69:326–330CrossRefPubMedPubMedCentral
17.
Mehta S, Armstrong BK, Kim SJ et al (2011) Long-term potency, sterility, and stability of vancomycin, ceftazidime, and moxifloxacin for treatment of bacterial endophthalmitis. Retina Phila Pa 31:1316–1322CrossRef
18.
Grzybowski A, Brona P, Kim SJ (2017) Microbial flora and resistance in ophthalmology: a review. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 255:851–862CrossRef
19.
Dave SB, Toma HS, Kim SJ (2011) Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study. Ophthalmology 118:2035–2040CrossRefPubMed
20.
Roth DB, Flynn HW (1997) Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy. Surv Ophthalmol 41:395–401CrossRefPubMed
21.
Dawis MA, Isenberg HD, France KA, Jenkins SG (2003) In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 51:1203–1211CrossRefPubMed
22.
Klugman KP, Capper T, Bryskier A (1996) In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 40:2802–2804CrossRefPubMedPubMedCentral
23.
Perrig M, Acosta F, Cottagnoud M et al (2001) Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother 47:701–704CrossRefPubMed
24.
Day CA, Marceau-Day ML, Day DF (1993) Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin. Antimicrob Agents Chemother 37:2506–2508CrossRefPubMedPubMedCentral
25.
Iyer MN, He F, Wensel TG et al (2006) Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci 47:317–319CrossRefPubMed
26.
(1995) Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 113(12):1479–1496
27.
Pershing S, Lum F, Hsu S et al (2020) Endophthalmitis after Cataract Surgery in the United States: A Report from the Intelligent Research in Sight Registry, 2013–2017. Ophthalmology 127:151–158CrossRefPubMed
28.
Patel SN, Gangaputra S, Sternberg P, Kim SJ (2020) Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol 65:408–420CrossRefPubMed
29.
Irigoyen C, Ziahosseini K, Morphis G et al (2012) Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 250:499–505CrossRefPubMed
Metadaten
Titel
Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience
verfasst von
Kenneth J. Taubenslag
Edward F. Cherney
Shriji N. Patel
Janice C. Law
Anthony B. Daniels
Stephen J. Kim
Publikationsdatum
25.05.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2023
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-023-06112-2

Weitere Artikel der Ausgabe 10/2023

Hyperreflective foci distribution in eyes with dry age-related macular degeneration with subretinal drusenoid deposits

  • Retinal Disorders

Association of open globe injury characteristics with outcome measures in the emergency department

  • Trauma

Fractal analysis of the macular region in healthy eyes using swept-source optical coherence tomography angiography

  • Retinal Disorders

Association of autoantibody levels with different stages of age-related macular degeneration (AMD): Results from the population-based Gutenberg Health Study (GHS)

  • Open Access
  • Retinal Disorders

Evaluation of scleral thickness in patients with Fuchs endothelial dystrophy

  • Cornea

Relationship between the main components of the crystalline lens and the anterior chamber depth after cataract formation

  • Open Access
  • Cataract

Neu im Fachgebiet Augenheilkunde

Kompetente Gesprächsführung

Mit schwierigen Gesprächen und der Übermittlung schlechter Nachrichten ist der Augenarzt/die Augenärztin im Krankenhaus und in der Praxis immer wieder konfrontiert. Eine gute Arzt-Patienten-Kommunikation basiert auf Respekt und Empathie und …

Sekundäre chorioidale Neovaskularisation – Wirklich so häufig?

Das Auftreten einer sekundären chorioidalen Neovaskularisation ist eine Komplikation im Rahmen einer chronischen Chorioretinopathia centralis serosa. Die Diagnose wird mittels multimodaler Bildgebung gestellt. Die Therapie erfolgt in der Regel mit …

Therapie der Chorioretinopathia centralis serosa im Vergleich – Mikrosekundenpulslaser versus photodynamische Therapie

Zum gegenwärtigen Zeitpunkt steht für die Behandlung der Chorioretinopathia centralis serosa (CCS) keine zugelassene Therapie zur Verfügung. Obwohl die CCS eine hohe Selbstresorptionsrate aufweist, können häufige Rezidive oder eine Chronifizierung …

Diagnostik und Klassifikation der Chorioretinopathia centralis serosa – Was brauche ich wirklich?

Die multimodale Bildgebung spielt bei der Diagnostik und Klassifikation der Chorioretinopathia centralis serosa (CCS) eine bedeutende Rolle. In diesem Beitrag sollen die wichtigsten Bildgebungsmodalitäten bei der CCS wie optische …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen